KILITCH DRUGS (INDIA) LTD. - 524500 - Clarification sought from Kilitch Drugs India Ltd
The Exchange has sought clarification from Kilitch Drugs India Ltd on April 09th, 2020 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited. KILITCH DRUGS (INDIA) LTD. - 524500 - Closure of Trading Window
Closure of Trading Window Kilitch Drugs India Ltd - 524500 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to SEBI circular no.SEBI/HO/MIRSD/DOS3/CIR/P/2018/139 dated November 6, 2018, pleased find enclosed herewith Newspaper Advertisement relating to transfer of shares. KILITCH DRUGS (INDIA) LTD. - 524500 - Outcome Of Board Meeting Held On February 14, 2020
Dear Sir/Madam, In continuation to our letter dated February 5, 2020, we wish to inform you that pursuant to Regulation 33 and Regulation 30 read with Para A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. February 14, 2020, have 1.Considered & approved the standalone and consolidated Un-audited financial results of the company for the quarter ended December 31, 2019; 2.Approved the re-appointment of Mr. Hemang Engineer as an Independent Director for a second term of 5 years w.e.f. 1st April, 2020, subject to Member's approval; 3.Approved the appointment of M/s. Deep Shukla & Associates, Company Secretaries to conduct Secretarial Audit of the Company for financial year ended 31st March, 2020; 4.Considered & approved the grant of additional 83869 options to the employees of the Company under ESOS Scheme. KILITCH DRUGS (INDIA) LTD. - 524500 - Board Meeting Intimation for To Consider And Approve The Standalone And Consolidated Un-Audited Financial Result Of The Company For The Quarter Ended December 31, 2019
KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2020 ,inter alia, to consider and approve 1. To Consider and approve the Standalone and Consolidated Unaudited Financial Result of the Company for the quarter ended December 31st, 2019; 2. To consider the re-appointment of Mr. Hemang Engineer as an Independent Director of the Company; 3. To consider the appointment of M/s. Deep Shukla & Associates, Company Secretaries to conduct Secretarial Audit of the Company for financial year ended March 31st, 2020; 4. Any other matter with the permission of the chair. Kilitch Drugs India Ltd - 524500 - Board Meeting Intimation for To Consider And Approve The Standalone And Consolidated Un-Audited Financial Result Of The Company For The Quarter Ended December 31, 2019
KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2020 ,inter alia, to consider and approve 1. To Consider and approve the Standalone and Consolidated Unaudited Financial Result of the Company for the quarter ended December 31st, 2019; 2. To consider the re-appointment of Mr. Hemang Engineer as an Independent Director of the Company; 3. To consider the appointment of M/s. Deep Shukla & Associates, Company Secretaries to conduct Secretarial Audit of the Company for financial year ended March 31st, 2020; 4. Any other matter with the permission of the chair. KILITCH DRUGS (INDIA) LTD. - 524500 - Shareholding for the Period Ended December 31, 2019
Kilitch Drugs India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 KILITCH DRUGS (INDIA) LTD. - 524500 - Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Harshal PatilDesignation :- Company Secretary and Compliance Officer Kilitch Drugs India Ltd - 524500 - Closure of Trading Window
With reference to the above subject, this is to inform you that pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time read with NSE Circular Reference no. NSE/CML/2019/11 and BSE Circular Reference no. LIST/COMP/01/2019-20, both dated April 02, 2019 Trading Window for dealing in Securities of the Company will remain closed for all Directors, Officers, Designated Persons of the Company and their immediate relatives with effect from Wednesday, January 1, 2020 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter ended December 31, 2019.